Co-Founder of the New York Cartilage Repair Society Eric Strauss, MD, an orthopedic surgeon with New York City-based NYU Langone Health, discusses the society and biggest trends in cartilage repair today.

The global spine biologics market is predicted to reach $2.7 billion by 2024, growing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.

Researchers at Central Queensland University in Australia are developing a 3D bioprint of crocodile cartilage to promote cartilage repair, ABC Capricornia reports.

UC San Diego researchers successfully derived spinal cord neural stem cells from human pluripotent stem cells, according to research published in Nature Methods.

To meet the growing demand for alternatives to spinal fusion, Kevin Pauza, MD, certified 14 spine specialists to perform the Discseel procedure at Weill Cornell Brain and Spine Center in New York City.

The global platelet rich plasma market is projected to increase from 2018 through 2026 at a 13.3 percent compound annual growth rate, according to a Credence Research report.

Pete O'Heeron is the founder and CEO of SpinalCyte.

Aziyo Biologics will exclusively distribute its bone repair product ViBone through RTI Surgical in the U.S.

Asterias Biotherapeutics provided an update from its ongoing phase 1/2a clinical trial of a stem cell treatment for severe spinal cord injury.

Ortho Regenerative Technologies earned extensions of expiry dates on certain warrants.

Johnson City, Tenn.-based Appalachian Orthopedics now offers cartilage restoration procedures.

Tom Cycyota is the president and CEO of AlloSource.

BioRestorative Therapies develops stem cell treatments for chronic back pain caused by disc degeneration.

Cerapedics began its investigational device exemption clinical trial for its P-15L Peptide Enhanced Bone Graft.

The global spine biologics market is projected to grow at a 4.4 percent compound annual growth rate, from $226 billion in 2018 to $280 billion by 2023, according to a Market Data Forecast report.

Orthopedic company 206 Ortho secured a patent for a new biocompatible composite designed to repair load-bearing bone and resorb without leaving a trace.

Atlanta-based Emory Orthopaedics & Spine Center earned a $13 million grant from The Marcus Foundation for a multicenter clinical trial to evaluate stem cell treatments for osteoarthritis.

Bone Biologics completed $5.9 million of financing.

Bioventus entered into a definitive agreement to divest its bone morphogenetic protein development program to a new Viscogliosi Brothers company.

Ortho Regenerative Technologies is an orthopedic biotechnology company developing novel therapeutic tissue repair devices for sports medicine surgeries.